Table 3.

Mean ± SD Ratings for Each Neuromotor Domain at Baseline and Endpoint in the Whole Sample and by Treatment Group

			Treatment Group						Overall Treatment Effect		Specific Treatment Effect
	Whole Sample		Haloperidol (n = 23)		Risperidone (n = 52)		Olanzapine (n = 25)
Neuromotor Domain	Baseline	4 Wk	Baseline	4 Wk	Baseline	4 Wk	Baseline	4 Wk	F1	P	F2	P
Parkinsonism	2.34 ± 3.61	3.62 ± 4.10	2.39 ± 4.09	4.04 ± 4.11	1.69 ± 2.93	3.81 ± 4.36	3.64 ± 4.19	2.84 ± 3.55	9.87	.002	2.78	.067
Dyskinesia	0.37 ± 0.88	0.20 ± 0.55	0.57 ± 1.16	0.30 ± 0.63	0.21 ± 0.69	0.12 ± 0.47	0.52 ± 0.91	0.28 ± 0.61	4.94	.001	0.29	.750
Akathisia	0.12 ± 0.53	0.43 ± 0.92	0.43 ± 1.03	1.13 ± 1.32	0.04 ± 0.19	0.31 ± 0.75	0.00 ± 0.00	0.04 ± 0.20	9.97	.002	9.32	< .001a
Catatonia	2.98 ± 5.28	0.94 ± 2.32	2.61 ± 4.37	0.65 ± 1.33	3.08 ± 5.87	1.12 ± 2.74	3.12 ± 4.92	0.84 ± 2.11	21.36	< .001	0.32	.723

^aHaloperidol > risperidone, olanzapine.